Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited said on Mar, 30 2026 that it will ask independent shareholders to approve three new guarantees with a combined maximum liability of roughly 585.8 million Singapore dollars.

The company plans to guarantee up to 266.8 million Singapore dollars of bank facilities for Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd.; up to 237.2 million Singapore dollars of bank facilities for Tianjin Zhongxin Medicine Co., Ltd.; and up to 81.8 million Singapore dollars of loans from Tianjin Pharmaceutical Group Finance Co., Ltd. to Tianjin Zhongxin Medicine.

All three counterparties are associates of controlling shareholder Tianjin Pharmaceutical Holdings, making the guarantees interested-person transactions under Singapore Exchange rules. Each facility will be backed jointly and severally by the company and Tianjin Pharmaceutical Holdings in proportion to their 43.35% and 56.65% stakes respectively.

The proposed guarantees represent about 44.2 % of the group’s net tangible assets of 7.0 billion renminbi as at Dec, 31 2025. No counter-guarantees will be obtained. The firm has 418.8 million renminbi of outstanding external guarantees and none are overdue.

Independent shareholders will vote on the resolutions at the annual general meeting scheduled for May, 15 2026. RHB Bank Berhad has been appointed independent financial adviser to opine on the transactions.